A Short Delay Is Still Bad News for AbbVie

The FDA extended the review for AbbVie's (NYSE: ABBV) Rinvoq as a treatment for psoriatic arthritis. Brian Orelli: So, last week, AbbVie said that the FDA is extending its review of Rinvoq as a treatment for psoriatic arthritis.